Advertisement

Eribulin Mesylate (E7389): Review of Efficacy and Tolerability in Breast, Pancreatic, Head and Neck, and Non–Small Cell Lung Cancer

  • Sarah L. Scarpace
    Correspondence
    Address correspondence to: Sarah L. Scarpace, PharmD, BCOP, Assistant Dean for Pharmacy Professional Affairs, Associate Professor, Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208
    Affiliations
    Department of Pharmacy Professional Affairs, Albany College of Pharmacy and Health Sciences, Albany, New York
    Search for articles by this author

      Abstract

      Background

      Eribulin mesylate is a halichondrin B analogue that acts as a nontaxane microtubule dynamics inhibitor. Eribulin was approved in the United States in 2010 for the treatment of metastatic breast cancer for patients who have received at least 2 metastatic breast cancer chemotherapeutic regimens, including an anthracycline and a taxane. Eribulin is administered as a single agent at 1.4 mg/m2 IV for 2 to 5 minutes on days 1 and 8 of a 21-day cycle.

      Objectives

      The goals of this article are to review eribulin's medication profile, including pharmacology, pharmacokinetic properties, efficacy, and tolerability. Recommendations are provided at the end of the article based on the published information.

      Methods

      PubMed, the Cochrane Central Register of Controlled Trials, and Clinical Trials.gov were searched from the beginning of each database through January 3, 2012, for relevant articles on human studies published in English. Search terms included eribulin, eribulin mesylate, and Halaven. Clinical trials, case reports, comparative studies, meta-analyses, evaluation studies, controlled clinical trials, and randomized controlled trials were included as search limits. The references from selected articles were also reviewed to identify additional publications. Eisai, the manufacturer of eribulin mesylate, was also contacted for information regarding trials listed in Clinicaltrials.gov but not yet published.

      Results

      One Phase III trial was identified that evaluated eribulin for use in patients with metastatic breast cancer. Four Phase II trials were identified that studied eribulin in patients with head and neck, pancreatic, and non–small cell lung cancers. The median overall survival among previously treated metastatic breast cancer patients treated with eribulin was 13.1 months compared with 10.6 months (P = 0.041) with other active chemotherapy for this setting. In non–small cell lung cancer, median overall survival in eribulin-treated patients has been reported as 9.4 months in an unselected population and varies according to taxane sensitivity: 12.6 months in taxane-sensitive disease versus 8.9 months in taxane-resistant disease. Patients with head and neck or pancreatic cancers did not experience improvements in response rates or survival outcomes when treated with eribulin in clinical trials.

      Conclusions

      Eribulin is approved by the Food and Drug Administration for patients with previously treated metastatic breast cancer and has demonstrated a survival benefit compared with standard treatment options in this setting. Non–small cell lung cancer patients had improved response rates when treated with eribulin in open-label, nonrandomized, Phase II trials reported in abstract form. Eribulin was not effective in the treatment of head and neck or pancreatic cancer in Phase II trials.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Halaven [package insert].
        Eisai Inc, Woodcliff Lake, NJ2010
        • Cortes J.
        • O'Saughnessy J.
        • Loesch D.
        • et al.
        • EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators
        Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study.
        Lancet. 2011; 377: 914-923
        • Spira A.I.
        • Iannotti N.O.
        • Savin M.A.
        • et al.
        A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small cell lung cancer.
        Clin Lung Cancer. 2012; 13: 31-38
        • Gitlitz B.
        • Davies A.
        • Belani C.
        • et al.
        A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane: a California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial.
        J Clin Oncol. 2009; 27: 15s
        • Arnold S.
        • Moon J.
        • Williamson S.
        • et al.
        Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.
        Invest New Drugs. 2009; 29: 352-359
        • Renouf D.J.
        • Tang P.A.
        • Major P.
        • et al.
        A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.
        Invest New Drugs. 2011; 29: 352-359
        • Goel S.
        • Mita A.
        • Mita M.
        • et al.
        A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
        Clin Cancer Res. 2009; 15: 4207-4212
        • Tan A.
        • Rubin E.
        • Walton D.
        • et al.
        Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
        Clin Cancer Res. 2009; 15: 4213-4219
        • European Medicines Agency
        CHMP Assessment Report for Halaven eribulin.
        (Accessed April 10, 2012)
        • Devriese L.A.
        • Merqui-Roelvink M.
        • Wanders J.
        • et al.
        Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
        Invest New Drugs. 2012; ([Epub ahead of print])
        • Michaud L.B.
        • Eckman K.
        Eribulin: another new chemotherapy for breast cancer.
        (Accessed January 4, 2012)
        • National Institute for Health and Clinical Excellence
        Final Appraisal Determination: eribulin for the treatment of advanced or metastatic breast cancer.
        November 2011 (Accessed January 4, 2012)